Yuvraj

Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.

Takeda Pharmaceutical from Japan said on December 17, 2025, that its experimental pill for a type of skin disease, which is developed using artificial...

Egypt has gone on to mark quite a prominent milestone when it comes to its biopharmaceutical development by laying the foundation stone for the...

Whether professionals need a high-performance gas chromatography system or a mass spectrometer, knowing where to look can help them stay under budget. The best...

For a $950 million upfront, Sobi is all set to get rights to pozdeutinurad - oral URAT1 inhibitor that performed pretty well in the...

Bicycle Therapeutics has entered into a 15-year agreement with the UK Nuclear Decommissioning Authority (NDA) to utilize reprocessed uranium from nuclear reactors for the...

Agilent Technologies Opens India Refurbishment Center to Advance Sustainable Science and Affordable Innovation New facility strengthens Agilent’s sustainability commitment and customer engagement; Education Center launched...